Glycemic Excursion, Adverse Drug Reactions, and Self-Management in Diabetes Patients Undergoing Chemotherapy: A Literature Review

Naoko Terao1,2, Kumi Suzuki2
1Graduate School of Nursing Doctoral Program, 2Faculty of Nursing, Osaka Medical and Pharmaceutical University, Osaka, Japan

Corresponding author: Naoko Terao, MSN, RN. Graduate School of Nursing Doctoral Program, Osaka Medical and Pharmaceutical University, Osaka, Japan. E-mail: terao.naoko.hv@ehime-u.ac.jp
Received: April 19, 2021; Accepted: July 20, 2021; Published: October 04, 2021

The purpose of this study was to identify the state of self-management in patients with diabetes who underwent chemotherapy, by referring to fluctuations in glycemic excursion and adverse drug reaction. We conducted a literature search in May 2021 using PubMed, CINAHL, and Ichushi-Web databases with “Cancer AND Diabetes AND Chemotherapy” as keywords. Based on our criteria, 25 articles were selected, and a review matrix sheet was created for the analysis of fluctuations in glycemic excursion and any adverse drug reaction to diabetes in patients undergoing chemotherapy. Substantial increases and unpredictable fluctuations in glycemic excursion were observed in these patients. In addition, an increase or change in the treatment dose was prevalent. Primarily, peripheral neuropathy and infection were reported as common adverse drug reactions. The risk of adverse drug reactions was especially high for patients with diabetes undergoing chemotherapy; furthermore, among this cohort, the detrimental effects were more likely to exacerbate into a severe condition that required special attention. Almost inevitably, the implementation rate of diabetes self-management programs decreased on the 8th week after the commencement of chemotherapy. Considering the findings of large individual differences in fluctuation in this cohort, tailored assistance that is appropriate for each patient’s chemotherapy regimen or blood glucose level is of paramount importance. Support of patient self-management to achieve stable blood glucose levels and thus prevent adverse drug reactions was a key component in the successful completion of chemotherapy and improved patient outcomes for this group of special needs patients.

Key words: Adverse drug reaction, chemotherapy, glycemic excursion, patients with both cancer and diabetes, self-management

Introduction
Worldwide, the number of patients with both diabetes and cancer has been increasing.1,2 In Japan, the leading cause of death among patients with diabetes from 2001 to 2010 was malignant neoplasm, accounting for about 38% of all cases.3 In the United States, malignant neoplasms are the second leading cause of death in patients with diabetes,
accounting for approximately 20% of all cases. Thus, malignant neoplasms are the leading cause of death in patients with diabetes. Since 90% of patients with diabetes are suffering from type 2 diabetes mellitus, it is reasonable to speculate that patients with both cancer and complications of type 2 diabetes mellitus are similarly on the rise. It is critical for type 2 diabetes mellitus patients to improve their daily lifestyle habits and maintain stable blood glucose and blood pressure levels to prevent the onset and worsening of diabetes-related complications and atherosclerotic diseases. However, improving lifestyle habits is not only difficult to change but also affects interpersonal relationships, work, and roles. Therefore, even if the need is known, it is difficult to put it into action. For this reason, self-management of patients with type 2 diabetes is focused on behavior change, motivation, and self-efficacy. In contrast, the introduction of self-management programs, appropriate for the specific treatment of tumors based on their location, is crucial for patients with cancer. As a result, when patients with diabetes are diagnosed with cancer and undergoing chemotherapy, they are forced to manage both diabetes and chemotherapy side effects, which increases the difficulty and complexity of self-management. Previous studies have reported that patients with diabetes undergoing chemotherapy experienced a decrease in self-management of diabetes 8 weeks after the start of chemotherapy. Moreover, patients experienced more glycemic variability and dietary changes during treatment compared to before cancer treatment. Diabetes mellitus has been shown to negatively affect the quality of life of physical and mental functions of patients undergoing chemotherapy. As shown above, chemotherapy in patients with type 2 diabetes mellitus leads to difficulties in self-management and deterioration of patients’ quality of life.

Especially for patients with diabetes who underwent chemotherapy, corticosteroids (steroids) used for antiemetic and allergy prevention can cause hyperglycemia. This risk of hyperglycemia or hypoglycemia associated with chemotherapy is alarming, particularly because accidents involving disorders of consciousness due to hyperglycemia or bone fracture owing to falls caused by hypoglycemia have been reported, and some of these cases can indeed be fatal. Clearly, controlling blood glucose levels during chemotherapy is a matter of life or death to patients with both cancer and diabetes. Physical weariness, susceptibility to infection, or diabetic neuropathy manifest simultaneously with adverse drug reactions to chemotherapy; this further exacerbates patient health and makes the continuation of chemotherapy difficult. Thus, the self-management of blood glucose levels and adverse drug reactions to chemotherapy become a key component of the safe completion of chemotherapy for patients with diabetes. Despite its relevance and effect on patient outcomes, the self-management issues concerning fluctuation in blood glucose levels or adverse drug reaction to chemotherapy of patients with diabetes have largely been overlooked. Therefore, the purpose of the present literature review was to illuminate the state of self-management among patients with diabetes undergoing chemotherapy in relation to fluctuation in their blood glucose levels or adverse drug reactions.

Methods
We used PubMed, CINAHL, and Ichushi-Web databases to conduct a literature search in May 2021 with the following keywords: “Cancer AND Diabetes AND Chemotherapy.” We did not establish any specific year range for this search. Out of 16,992 articles returned in our search, 953 articles were selected based on the following criteria: A peer-reviewed, original article published in an academic or professional journal of English or Japanese language whose participants were 19 years of age or older. After reading abstracts from 953 articles, 928 articles that did not report on patients with diabetes undergoing chemotherapy were excluded, which left us with 23 articles. After adding two articles found in-person, a total of 25 articles remained for analyses: 17 articles in English and 8 articles in Japanese [Figure 1]. A review matrix sheet with a table that listed the following items and topics was created to analyze the content and trend involving self-management, fluctuations in blood glucose levels, and adverse drug reactions to chemotherapy: The date of publication, survey country, research design, the purpose of the study, the type of study, attributes, cancer type, cancer stage, chemotherapy treatment plan (regimen), usage of steroids during chemotherapy, classification of diabetes mellitus, blood glucose, or glycated hemoglobin (HbA1c) levels, and the manifestation of adverse drug reactions. The first author (N.T) extracted the references for analysis, and then discussed and confirmed with the co-researcher (K.S) whether the extracted references were appropriate for analysis.

Results
Research overview of patients with diabetes undergoing chemotherapy
The overwhelming majority of the study designs were quantitative: 22 studies out of 25. Observational studies were the most common, with 14 cases. The study focus was as follows: Fluctuations in blood glucose levels during chemotherapy (n = 6), adverse drug reaction to chemotherapy (n = 13), and patient self-management (n = 6). The types of cancer observed in most participants were a
combination of solid carcinoma and hematologic cancer. For those studies that specified the tumor location, four out of fourteen concerned breast cancer. On the other hand, the locations of tumors in other studies were diverse. Regarding cancer stage, studies that included stages I to IV ($n = 9$) and I to III ($n = 3$) were common. Only two studies specified one specific type of chemotherapy regimen while others either made no statement or involved a combination of various regimens. Most studies did not provide details of diabetes type, or blood glucose, or HbA1c levels. Participants were predominantly older: The average age of the participants from 18 studies was 60 years or older. The scale of the studies varied widely ranging from four to 14,000 participants; of 24 studies, 19 studies were small, with <100 participants [Table 1].

Fluctuations in blood glucose levels of patients with diabetes undergoing chemotherapy

All the participants in the reviewed studies had used steroids during chemotherapy. The highest recorded levels of blood glucose during chemotherapy were over 300 mg/dl. The surge in blood glucose levels occurred within a few hours of anticancer drug treatment, peaked at approximately 10 h, and dropped after 24 h. The mean fasting blood glucose level was significantly increased from 131.4 ± 37.2 mg/dl before treatment to 163.8 ± 52.3 mg/dl before breakfast on the day after treatment ($P < 0.01$). Hyperglycemia was detected in 80% of the 40 patients during the first course of chemotherapy and 60% during the fifth course. The achievement rate of glycemic control goals by steroid type was 54% for dexamethasone and 87% for prednisolone among 40 patients, with dexamethasone being significantly lower than prednisolone ($P < 0.05$). Significant positive correlations were identified (blood glucose: $r = 0.697$; HbA1c: $r = 0.712$; $P < 0.01$) between cumulative doses of dexamethasone and the increase in the levels of blood glucose and HbA1c. When cumulative doses of dexamethasone reached over 150 mg, significant increases in blood glucose and HbA1c levels were identified ($P < 0.01$).
### Table 1: Characteristics of reviewed studies

| First author (publication year) | Research design | Number of participants | Average age or median (years) | Type of cancer | Cancer stage | Average blood glucose level (mg/dl) or HbA1c (%) | The state of steroid medication | Regimen | State during chemotherapy |
|---------------------------------|-----------------|------------------------|-----------------------------|----------------|-------------|-----------------------------------------------|---------------------------------|---------|----------------------------|
| Kunitake et al., (2020) Japan    | Qualitative     | 6                      | 52.7                        | Pancreatic, biliary | 1~IV        | 7.3                                           | NR                              | GEM, GS, NabPTX                | Patients were trying to grasp their own bodies as diabetic more than before the onset of cancer |
| Kikuchi and Fujino (2020) Japan  | Qualitative     | 7                      | 67.1                        | Colon            | NR          | 7.6                                           | NR                              | XELOX, FOLFIry, XELOX + Bev    | Patients were experiencing numbness in their fingertips and could not take their blood glucose readings, so they had to retake the blood glucose test |
| Molassiotis et al., (2019) Hong Kong, Singapore, UK | Observational | 37                     | 54.2±9.2                    | Solid tumor      | 1~IV        | NR                                           | NR                              | Taxanes, platinum, combined    | Diabetes showed a trend (P<0.05) with sensory CIPN only |
| Zylla et al., (2019) USA | Observational  | 330                    | 64.6                        | Solid tumor, hematological tumor | 1~IV | 7.1% ±1.4% | Available (details unknown) | NR | At least one glucose test >300 mg/dl, and a higher HbA1c |
| Gaballah et al., (2018) Egypt | Observational   | 54                     | 50.1±11.5                   | NR               | NR          | NR                                           | NR                              | Cisplatin, oxalaplatin, paclitaxel, docetaxel | A significant correlation was noted between the presence of diabetes and incidence of CIPN |
| Lega et al., (2018) Canada | Cohort | 4955                   | 66.8                        | Breast           | 1~III       | NR                                           | NR                              | NR | With oxalaplatin, no factor affected the occurrence or grade of CIPN |
| Goebel et al., (2016) USA | Qualitative     | 5                      | 59.4±6.5                    | Breast, colon, lymphoma | NR | NR                                           | NR                              | NR | Among woman with Stage III breast cancer, in whom chemotherapy is considered guideline-adherent treatment, those with diabetes were slightly less likely to receive chemotherapy than those without diabetes |

Contd...
| First author (publication year)/survey country | Research design | Number of participants | Average age or median (years) | Type of cancer | Cancer stage | Average blood glucose level (mg/dl) or HbA1c (%) | The state of steroid medication | Regimen | State during chemotherapy |
|----------------------------------------------|-----------------|------------------------|-------------------------------|----------------|-------------|---------------------------------------------|-------------------------------|---------|-----------------------------|
| Kus et al., (2016)[31]/Turkey | Observational | 81 | NR | NR | NR | NR | Taxanes | Patients receiving the taxane and platinum combination arm were evaluated independently. Neuropathy developed in 81.8% of diabetic patients (P<0.05). In the taxane-only therapy group (n=170), neuropathy development was observed in 45.5% (n=61) of non-diabetic and 52.5% (n=31) of diabetic patients (P<0.05). In the taxane and combination group, 34.6% of diabetic patients developed neuropathy of > Grade 2 (P<0.001). Diabetic patients having a duration of >5 years showed high incidences of neurotoxicity. |
| Park et al., (2015)[32]/Republic of Korea | Observational | 97 | 61.8±12.1 | Solid tumor | I–IV | NR | Alkylating agents, antimetabolites, anthracyclines, etc. | The decision tree analysis identified underlying diabetes and the alkylating agent regimen as the greatest risk factors for infections in patients undergoing chemotherapy. In the subset of subjects with diabetes or combination of diabetes and hypertension, the likelihood of infection was 25.3% |
| Hershey and Pierce (2015)[33]/USA | Exploratory | 41 | 64.6±9.5 | Solid tumor, hematological tumor | I–IV | NR | NR | Patients who had diabetes experienced increased severity only for appetite and nausea. Patients started with moderate fatigue that tended to increase slightly. Levels of self-efficacy were significantly higher (P<0.01) for diabetes patients who responded "completely agree" than "somewhat agree" to a questionnaire item that stated "I would like to focus on treatments for both cancer and diabetes because both diseases are curable." |
| Higo et al., (2015)[34]/Japan | Observational | 34 | 61.9±4.6 | Solid tumor, hematological tumor | | 7.1%±0.8% | NR | Levels of self-efficacy were significantly higher (P<0.01) for diabetes patients who responded "completely agree" than "somewhat agree" to a questionnaire item that stated "I would like to focus on treatments for both cancer and diabetes because both diseases are curable." |
| Brady et al., (2014)[35]/Japan | Observational | 40 | 61 | ALL, lymphoma | | 220.6 mg/dl (blood glucose level during fasting) | Dexamethasone Hyper-CVAD (40 mg) by mouth daily for four consecutive days | Analysis of insulin dosage on demographic and clinical characteristics showed higher doses in patients with higher body mass index. Hyperglycemia occurred in 80% of glucose measurements in Cycle 1 compared with 60% of Cycle 5 measurements; this was statistically significant. |

Contd...
| First author (publication year)/survey country | Research design | Number of participants | Average age or median (years) | Type of cancer | Cancer stage | Average blood glucose level (mg/dl) or HbA1c (%) | The state of steroid medication | Regimen | State during chemotherapy |
|-----------------------------------------------|-----------------|------------------------|-----------------------------|----------------|-------------|-----------------------------------------------|-------------------------------|----------|--------------------------|
| Hershey et al., (2014)[14]/USA              | Exploratory     | 41                     | 64.0±9.6                    | Solid tumor,  hematological tumor | Early and late | NR                                           | NR                           | NR       | When compared with baseline, cancer patients with diabetes performed significantly fewer self-management activities for diabetes after a minimum of 8 weeks of chemotherapy |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
| Takenaka et al., (2013)[36]/Japan           | Observational   | 6                      | 63                          | Head and neck  | II~IV       | NR                                           | NR                           | TPF, DC  | Tube feeding and the presence of diabetes were both independent of predictor variables of febrile neutropenia |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
| Dote et al., (2013)[37]/Observational Japan | Observational   | 40                     | 72.5                        | Hematological tumor | NR            | Prednisolone, 40 mg/day; dexamethasone, 19.8 mg/day | Anthracycline and cytarabine; CHOP, etc. | Prednisolone administered group (P<0.05) | Prominently high level of hyperglycemia (above 300 mg/dl) was detected |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
| Vincenzi et al., (2013)[38]/Italy            | Exploratory     | 29                     | <60 or ≥60: 50%             | Colon            | NR          | NR                                           | FOLFOX4                      |                     | The rate of achieving the goal for blood glucose control was significantly lower for the dexamethasone administered group than the prednisolone administered group (P<0.05) |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
| Tanimoto et al., (2013)[39]/Japan           | Observational   | 20                     | 64.0±12.1                   | Gynecologic     | I~IV        | Used by 95% of patients                        | Taxanes and Platinum, CPT11 and Platinum, etc. | FOIFOX4  | The treatment plan for diabetes had to be changed during chemotherapy for four patients (20%) due to the challenge associated with blood glucose control |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |
|                                               |                 |                        |                             |                 |             |                                               |                               |          |                          |

Contd...
| First author (publication year)/ survey country | Research design | Number of participants | Average age or median (years) | Type of cancer | Cancer stage | Average blood glucose level (mg/dl) or HbA1c (%) | The state of steroid medication | Regimen | State during chemotherapy |
|-----------------------------------------------|----------------|-----------------------|-------------------------------|----------------|-------------|-----------------------------------------------|----------------------------------|---------|--------------------------|
| Uwah et al., (2012)USA                        | Observational  | 15                    | 60.2                          | Colon          | NR          | NR                                            | Oxaliplatin-induced              | Patients with diabetes developed neuropathy at a significantly lower mean cumulative dose of 388 mg/m² |
| Hershey et al., (2012)USA                     | Action research| 76                    | NR                            | Breast, colon, lung, other | NR          | NR                                            | NR                              | From the fifth cycle of chemotherapy, patients with diabetes showed a higher chance of developing OXIPN than patients without diabetes. |
| Tsuda et al., (2012)Japan                     | Observational  | 7                     | 53.2±10.7                     | Breast         | NR          | NR                                            | FEC, CE, AI                      | The presence of diabetes negatively impacted physical function and mental health in patients undergoing chemotherapy. |
| Wuketich et al., (2012)Vienna                 | Cross-sectional research | 168                   | 66-75, 50.8%, 76-80, 49.2%   | Solid tumor    | 1~IV       | NR                                            | Gemcitabine, taxanes, oxaliplatin, etc. | Patients with and without diabetes aged ≤59 years had similar levels of mental health. Mental health improved in patients with diabetes aged 60-69 years, but declined in patients with diabetes and cancer >70 years. |
| Fuji et al., (2012)Japan                      | Observational  | 14                    | 61.6±7.2                      | Solid tumor    | 1~IV       | NR                                            | GEM, FOLFOX, FOLFIRI, etc.       | It was speculated that diabetes patients undergoing paclitaxel chemotherapy were at high risk of developing grade ≥3 peripheral nerve disorder. |
| Saito et al., (2011)Japan                     | Observational  | 4                     | 67.7±9.6                      | Gynecologic    | 1~IV       | NR                                            | Dexamethasone cumulative dose after: 3 months, 46.4 mg; 6 months, 91.7 mg; 12 months, 157 mg | The blood glucose levels of diabetes patients with cancer who were administered dexamethasone for 12 months were significantly higher (P<0.05) than those for diabetes patients who had received diabetic treatment for more than 1 year without a history of anti-cancer and steroid therapies including dexamethasone. A significant positive correlation was identified between a 12 month cumulative dose of dexamethasone and the change in blood glucose and HbA1c levels over 12 months (P<0.01). When a cumulative dose of dexamethasone exceeded 150 mg, the capacity of variation in blood glucose or HbA1c levels over a 12 months period was positively significant. Although the type or dosage of antidiabetic drug were adjusted for approximately half of the patients, levels of blood glucose and HbA1c increased with the cumulative dose of dexamethasone. Changes in the treatment plan such as the unit change in insulin, increase in the dosage of internal medicine, or introduction of different type of insulin were made for 4 patients (28.6%). Blood glucose level was heightened by dexamethasone even for those patients with excellent blood glucose control before chemotherapy. A significant increase in blood glucose levels was identified in all cases after the administration of dexamethasone (P<0.05). Peak blood glucose levels were observed about 10 h after the intravenous administration of dexamethasone. Increases in blood glucose level due to dexamethasone were transitory; they became apparent a few hours after administration, but then decreased after 24 h. |

Contd...
Terao And Suzuki: Diabetes Patients Undergoing Chemotherapy

Regarding hypoglycemia, that focused on type 2 diabetes mellitus patients who received Hyper-Cyclophosphamid Doxorubicin Vincristine and Dexamethasone Chemotherapy (Hyper-CVAD) to counter hypoglycemia, demonstrated that while blood glucose levels of several patients decreased to 70 mg/dl or lower, it did not fall <40 mg/dl. Furthermore, no studies to date report on patients who developed hypoglycemia who received similar treatment. Twenty percent of the patients' treatment plans were modified during chemotherapy. Type 2 diabetes mellitus patients who received Hyper-CVAD were administered with 1.2–1.3 units of insulin per 1 kg of body weight, and this dose was increased when the patients were overweight. A sliding scale method which determines the dosage of insulin based on blood glucose levels was used for patients who received periodic insulin doses. The treatment plan for approximately half of the patients was changed by adjusting the dosage or type of antidiabetic drug; as the cumulative dose of dexamethasone was increased in these patients, levels of their blood glucose and HbA1c rose correspondingly. Even with a small dose of prednisolone, some cases required an active increase in insulin dose.

Adverse drug reaction to patients with diabetes undergoing chemotherapy

There were 13 studies on side effects seen in patients with diabetes undergoing chemotherapy, the main ones were as follows: Peripheral nerve disorder, 6 cases; infectious, 3 cases; oral mucositis and heart failure, 1 case; nonspecific, 2 cases.

Peripheral nerve disorder

In studies with more than 50 patients, patients with a medical history of diabetes comprised approximately 60%–80% of those patients who manifested peripheral nerve disorder. In particular, 52% of patients with diabetes for <5 years and 75% of patients with diabetes for more than 5 years developed peripheral nerve disorder. The incidence of peripheral nerve disorder was higher among patients with diabetes with the duration of five or more years than for those counterparts with <5 years (P < 0.01). On the other hand, a study with <30 patients reported that there was a nonsignificant correlation between the presence of diabetes and clinical grading of peripheral nerve disorder. The degree of symptoms ranged from Grade 2 to Grade 3 in the Common Terminology Criteria for Adverse Events and the symptoms progressively worsened after each chemotherapy treatment. However,
studies with fewer than 30 patients, reported that there was a nonsignificant correlation between the presence of diabetes and clinical grading of peripheral nerve disorder.\(^{[8]}\) It was difficult to distinguish whether the peripheral nerve disorder was caused by worsening diabetes or the side effects of chemotherapy, and some patients were confused.\(^{[30]}\)

Moreover, the likelihood of symptom emergence was significantly higher after the fifth course for patients with diabetes who received chemotherapy with oxaliplatin.\(^{[6]}\) The only symptom of peripheral nerve disorder that emerged was sensory neuropathy.\(^{[36]}\)

There were no significant differences in the occurrence of peripheral nerve disorder between patients with or without diabetes when taxane-only chemotherapy was applied.\(^{[31]}\) Regimens that were significantly more likely to occur in patients with diabetes were those that included taxanes and platinum, FOLFOX4 (5-fluorouracil, leucovorin, oxaliplatin), and oxaliplatin.\(^{[31,38,40]}\) The cumulative dose of oxaliplatin at the onset of symptoms was 388 mg/m\(^2\); even with a small dose, peripheral nerve disorder emerged in patients with diabetes.\(^{[40]}\)

**Infection**

In a study of patients who received intravenous chemotherapy with steroids, the probability of new infection was increased by 68% in those patients with diabetes compared to counterparts without diabetes. In addition, the rate of hospitalization for infection during the 1\(^{st}\) year after initial chemotherapy was 37.0% in patients with diabetes and 29.2% in patients without diabetes, within 1 year after receiving their first chemotherapy, the admission rate to the hospital was about 8% higher for patients with diabetes (\(P < 0.01\)).\(^{[27]}\) Alkylation agent chemotherapy was the primary factor contributing to infectious disease in these patients.\(^{[32]}\) The highest onset of risk factors was observed in diabetes with high blood pressure or tube feeding.\(^{[32,36]}\) None of the following were associated with the onset of infectious disease: HbA1c level, cancer stage, age, and gender.\(^{[27]}\)

**Oral mucositis**

Chemotherapy-induced oral mucositis occurred in 5.9% of patients without diabetes and 6.9% of patients with diabetes, with significantly more patients with diabetes developing the disease compared to patients without diabetes (\(P < 0.05\)).\(^{[42]}\)

**Other side effects or adverse drug reactions**

Patients with diabetes tend to develop severe anorexia, nausea, and physical weariness.\(^{[33]}\) In a study that investigated patients’ symptoms during chemotherapy using The Symptoms of Illness Checklist, which consists of 33 items, symptoms during chemotherapy in patients with diabetes were significantly more severe 8 weeks after the start of chemotherapy compared to before.\(^{[14]}\) Among patients aged 66 years or older receiving adjuvant chemotherapy for breast cancer, more patients with diabetes were hospitalized outside the treatment period (32.7%) and patients without diabetes (25.1%) (\(P < 0.01\)). The reasons for hospitalization were infection, neutropenia, and anemia.\(^{[45]}\) Diabetes was a predictor for the onset of heart failure for those patients with breast cancer undergoing chemotherapy.\(^{[46]}\)

**Self-management for patients with diabetes undergoing chemotherapy**

Some patients with diabetes undergoing chemotherapy responded that they wished to concentrate on treatment for both cancer and diabetes\(^{[34]}\) although other patients solely focused on cancer treatment simply because “killing two birds with one stone” was not feasible.\(^{[29,30]}\) Self-management of diabetes among patients with diabetes undergoing chemotherapy who developed solid tumors was investigated with the Self-care Inventory-Revised (SCI-R), which examines patients’ attitudes toward adherence to self-care recommendations regarding diabetes, and the results showed that patients with diabetes’ self-management of diabetes decreased significantly 8 weeks after the start of chemotherapy (\(P < 0.01\)).\(^{[45]}\) Hindering factors included: Physical weariness, nausea, change in the sleep cycles, degrees of severity in symptoms, and unavailability of advice from medical staff about dietary intake with diabetes in mind.\(^{[14,30]}\) Specifically, physical weariness and nausea prevented optimal dietary intake and implementation of exercise therapy. Other obstacles included: Hyperphagia due to steroids, the fact that the patient was recommended to eat anything regardless of fluctuations in blood glucose, and the challenge associated with oral administration of hypoglycemic agents when suffering from nausea.\(^{[30]}\) Some patients had difficulty in performing self-monitoring of blood glucose because of peripheral neuropathy.\(^{[25]}\) This naturally raised a question regarding the traits of patients whose implementation rates for diabetes self-management were high even at 8 weeks into chemotherapy. The profile of such patients included: Disease duration for diabetes was long, self-efficacy and levels of expected outcome were high, control of blood glucose levels after chemotherapy were excellent, and the number of prescribed drugs was few.\(^{[14,30]}\) The differences in SCI-R by cancer site were not clarified.\(^{[14]}\)

**Discussion**

**Research trend concerning patients with diabetes undergoing chemotherapy**

Most of the studies on patients with diabetes during chemotherapy were related to the frequency and severity
of symptoms of adverse effects of chemotherapy, especially peripheral neuropathy and infection. However, most of the studies did not analyze the frequency and severity of side effect symptoms for each chemotherapy regimen received by the subjects. The risk of emetic and peripheral nerve disorder differs depending on the type of anticancer drug used. [47, 48] Therefore, a regimen-specific analysis is needed in the future. The only study of glycemic variability was in patients with diabetes undergoing chemotherapy with steroids. Because of the variety of steroids administered and the lack of clarification of the status of blood glucose control before chemotherapy, future studies are needed to standardize the conditions of the subjects and to include the status of blood glucose control before chemotherapy in the survey items.

Fluctuations in blood glucose levels of patients with diabetes undergoing chemotherapy

Multiple studies show that blood glucose levels in patients with diabetes increase more than 300 mg/dl after undergoing chemotherapy. [49, 50] Elevated blood glucose levels have the potential to detract from the beneficial effects of chemotherapy. [49] Furthermore, when blood glucose levels exceed 250 mg/dl, the risk of diabetic ketoacidosis, an acute complication of diabetes, is increased, thereby causing dehydration and a reduction in blood pressure. [50] Moreover, if such elevated blood glucose persists, it could lead to other complications of diabetes. [51] Thus, the prevention of elevated blood glucose levels is of paramount importance for patients with diabetes undergoing chemotherapy. Despite its relevance to the treatment of this group of special needs patients, there is no consensus on the appropriate glycemic control target for patients with diabetes undergoing chemotherapy. [52] Therefore, accurate blood glucose control, responsive to the unique fluctuation of blood glucose levels of each patient, is indispensable.

Another challenge for patients with diabetes undergoing chemotherapy lies in the common inclusion of the steroids prednisolone and dexamethasone. [53] There is a clear difference between prednisolone and dexamethasone’s half-life in the blood, at 2.5 h and 3.5 h, respectively. [54] Therefore, the remaining effect of elevated blood glucose from the previous day makes the control of blood glucose levels challenging, especially when therapy includes a daily administration of dexamethasone. [43] To respond to this challenge, the identification of patient-specific steroids and assessment of their blood glucose level fluctuation before the commencement of chemotherapy should never be overlooked.

Other strategies for minimizing fluctuation in blood glucose levels during chemotherapy include increasing the dose of oral antihyperglycemic agent and insulin or scheduling extra administration of insulin. However, by performing such strategies, it is apparent that the risk of hypoglycemia will also be magnified. Nevertheless, the extant literature, containing a small sample size of fewer than 40 patients, reports either mild cases of hypoglycemia in a few patients [55] or no hypoglycemia. [56] Due to these missing details, for those drugs with an antihyperglycemic effect used in the aforementioned studies, further acquisition of data concerning hypoglycemia during chemotherapy is warranted.

Side effects that emerged in patients with diabetes undergoing chemotherapy

Compared to patients without diabetes undergoing chemotherapy, some studies show that patients with diabetes undergoing chemotherapy are more likely to manifest peripheral nerve disorder. [28, 31, 40] Peripheral nerve disorder is a notable side effect that warrants the undivided attention of all medical staff involved in the treatment of patients with diabetes undergoing chemotherapy. Peripheral nerve disorder is highly likely if hyperglycemia persists. [55] Furthermore, because steroids are involved in chemotherapy, patients with diabetes are prone to developing hyperglycemia during this treatment. [56] Consequently, the time at which the steroid is introduced becomes the turning point, when peripheral nerve disorder is induced in patients with diabetes.

The following secondary physical disabilities or symptoms are likely to occur in patients with diabetes who develop peripheral nerve disorder: Inability to perform grip actions or actions in minute detail, aching pains caused by cold stimulation, and instability while walking. [57] Such development of peripheral nerve disorders, particularly in patients with diabetes, that are caused by chemotherapy raise a variety of concerns. First, the risk of not being able to conduct blood sugar determination or perform insulin self-injection becomes pronounced due to a weakened grasp on a blood glucose meter or tools used for insulin self-injection. Second, patient distress could soar from the cold stimulation-induced pain they experience every time they disinfect themselves with alcohol when conducting blood sugar determination. Thirdly, owing to their poorer gait while standing or walking, caused by peripheral nerve injury in the lower extremity, the risk of falling during exercise rehabilitation increases; fear of this may prevent such patients from participating in rehabilitation.

These concerns all point to the need for assistance in self-management against peripheral nerve disorder for patients with diabetes, especially from an early stage of chemotherapy. Several studies [31, 38, 40] demonstrate that the severity of symptoms is likely to be heightened when patients with diabetes undergoing chemotherapy receive
a regimen comprising a combination of taxane and the platinum anticancer drugs, FOLFOX4, and oxaliplatin. These drugs are known to induce the development of peripheral nerve disorder.\textsuperscript{[58]} It is therefore essential for medical professionals to carefully assess the presence of peripheral nerve disorder before the commencement of chemotherapy or the introduction of those drugs. How symptoms of peripheral nerve disorder manifest in patients with diabetes at an early stage of chemotherapy and how the severity of their symptoms affect the quality of their daily lives, along with their self-management, must be clarified through a systematic assessment. This is crucial, because, when compared to patients without diabetes, patients with diabetes undergoing chemotherapy are more susceptible to infection.

\textbf{Self-management of patients with diabetes undergoing chemotherapy}

Literature shows that patients with the following characteristics demonstrate superior self-management of diabetes while undergoing chemotherapy: A longer diabetes disease duration,\textsuperscript{[14,30]} high self-efficacy for blood glucose control, well-managed blood glucose levels before chemotherapy, and a lower number of drugs per prescription. This underscores the importance of patient support that acknowledges the patient’s record and their ability for blood glucose control. Still, owing to the limited number of currently available studies, the real state of self-management among patients with diabetes undergoing chemotherapy is yet to be investigated. Further studies addressing the management of the side effects of chemotherapy and blood glucose level control in patients with diabetes undergoing chemotherapy should provide a basis for developing appropriate support programs of self-management for this group of special needs patients.

\textbf{Limitations}

Although this review makes an important contribution to our understanding of fluctuations in blood glucose levels in each regimen of chemotherapy for patients with diabetes, the overview gained from the literature was limited by missing details in diabetes or cancer information. This prevented us from assembling a meta-analysis of changes in blood glucose levels for each chemotherapy regimen or the effect of various doses of steroids on blood glucose levels. In addition, we could not determine at which phase of chemotherapy the symptoms appeared because there was no information on the observation period, although the symptoms appeared differently with time. Finally, there remains the possibility that not all cases have been considered since our review only focused on papers written in English or Japanese languages.

\textbf{Conclusions}

Patients with diabetes undergoing chemotherapy were given increased doses of hypoglycemic agents or additional doses of hypoglycemic agents to control their blood sugar because of hyperglycemia. Compared to patients without diabetes, patients with both cancer and diabetes are burdened with a higher risk of developing side effects of chemotherapy, particularly peripheral nerve disorder and infectious diseases; both unwanted side effects are more likely to become severe among patients with diabetes than those without. The fact that infectious diseases could prove fatal and that peripheral nerve disorders tend to worsen, lead to a substantial deterioration in patient quality of life. This underscores the importance of timely support for this rapidly emerging group of special needs patients with cancer. Unequivocally, there is an urgent need for a support program based on systematic research that clarifies strategies for the control and self-management of blood glucose levels and adverse drug reactions in patients with diabetes undergoing chemotherapy. Such an endeavor would assist this group of special needs patients who are suffering from two of the most prevalent modern diseases: Diabetes and cancer.

\textbf{Financial support and sponsorship}

This work was supported by JSPS KAKENHI (Grant No. 20K19054).

\textbf{Conflicts of interest}

There are no conflicts of interest.

\textbf{References}

1. International Diabetes Federation. 9th Edition of IDF Diabetes Atlas; Chapter 1 What Is Diabetes? Belgium: 2019. p. 4. Available from: https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf. [Last accessed on 2020 Nov 23].

2. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941-53.

3. Nakamura J, Kamiya H, Haneda M, Inagaki N. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010-report from the committee on the cause of death in diabetes mellitus. J Japan Diabetes Soc 2016;59:667-84.

4. Gregg ED, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: An epidemiological analysis of linked national survey and vital statistics data. Lancet 2018;391:2430-40.

5. International Diabetes Federation. 9th Edition of IDF Diabetes Atlas; Chapter 1 What Is Diabetes? Belgium: 2019. p. 14. Available from: https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf. [Last accessed on 2020 Nov 23].
6. Certification Board for Diabetes Educators in Japan. Diabetes Educators Guidebook 2020 Learning Objectives and Tasks for Certified Diabetes Educator: System for Certified Diabetes Educator of Japan. Tokyo: Medical Review Sha; 2020. pp. 2.

7. The Japan Diaberes Society. Diabetes Treatment Guide 2020-2021. Tokyo: Bunkodo; 2020. p. 31.

8. Espinoza P, Varela CA, Vargas IE, Ortega G, Silava PA, Boehner KB, et al. The burden of treatment in people living with type 2 diabetes: A qualitative study of patients and their primary care clinicians. PLoS One 2020;15:e0241485.

9. Tanenbaum ML, Kane NS, Kenowitz J, Gonzalez JS. Diabetes distress from the patient’s perspective: Qualitative themes and treatment regimen differences among adults with type 2 diabetes. J Diabetes Complications 2016;30:1060-8.

10. Tsutsui H, Nomura K, Kusunoki M, Ishiguro T, Ohkubo T, Ohsida Y. Gender differences in the perception of difficulty of self-management in patients with diabetes mellitus: A mixed-methods approach. Diabetol Int 2016;7:289-98.

11. Certification Board for Diabetes Educators in Japan. Diabetes Educators Guidebook 2020 Learning Objectives and Tasks for Certified Diabetes Educator: System for Certified Diabetes Educator of Japan. Tokyo: Medical Review Sha; 2020. p. 116-7.

12. Ogasa M. The current status and issues of self-management scale in recuperation of patients with chronic disease. J Japan Soc Nurs Res 2017;41:85-97.

13. Ozawa M, Arita H. Life adjustments and thoughts regarding the next cycle of in outpatients undergoing chemotherapy. J Jpn Soc Cancer Nurs 2020;34:180-8.

14. Hershey DS, Given B, Given C, Corser W, von Eye A. Predictors of diabetes self-management in older adults receiving chemotherapy. Cancer Nurs 2014;37:97-105.

15. Nakagawa S, Inagaki M, Tsaki K. Experience of cancer treatment in type 2 diabetes patients with head and neck cancer. J Jpn Acad Diabetes Educ Nurs 2019;23:155-62.

16. Hershey DS, Given B, Given C, Von Eye A, You M. Diabetes and cancer: Impact on health-related quality of life. Oncol Nurs Forum 2012;39:449-57.

17. Japan Society of Clinical Oncology; Clinical Practice Guideline Ver 2.2. 2018. Available from: http://jSCO-cpg.jp/guideline/29.html#cq05. [Last accessed on 2020 Nov 23].

18. Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J, et al. Overview of taxol safety; JNCI Monogr 1993; 15:131-9.

19. Yamamoto T, Hirano T. How to deal with serious side effects of medicines and the relief system drug-related hyperglycemia. Showa Univ J Med Sci 2015;75:426-31.

20. Japan Council for Quality Health Care. Medical Accident Information Collection Project; 2020. Available from: http://www.med-safe.jp/mpsearch/SearchReport.action. [Last accessed on 2020 Nov 23]

21. Sanke T. Symptoms of diabetes. In: Nanjo K, editor. Update Medical Course for Nursing, 2nd ed. Vol. 8. Tokyo: Diabetes and Complications Nakayama Shoten; 2011. p. 27-8.

22. Ono Y. Impaired neutrophil function in patients with diabetes. Jpn J Chemother 2016;64:735-43.

23. Hotta N. Symptoms of diabetes. In: Nanjo K, editor. Update Medical Course for Nursing, 2nd ed. Vol. 8. Tokyo: Diabetes and Complications Nakayama Shoten; 2011. p. 358-62.

24. Kunitake Y, Nagasaki I, Majima T. The experiences of pancreatic and biliary cancer outpatients with diabetes during chemotherapy. J Chiba Acad Nurs Sci 2020;26:1-9.

25. Kikuchi Y, Fujino F. Cancer chemotherapy experiences of patients with type 2 diabetes. J Grad Sch Nurs Sci Himeji Univ 2019;3:67-76.

26. Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JS, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9:E01312.

27. Zyalla D, Gilmore G, Eklund J, Richter S, Carlson A. Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy. J Diabetes Complications 2019;33:335-9.

28. Gaballah A, Shafik A, Elhusseiny K, Ashraf M. Chemotherapy-induced peripheral neuropathy in Egyptian patients: Single institution retrospective analysis. Asian Pac J Cancer Prev 2018;19:2223-7.

29. Lega IC, Austin PC, Fischer HD, Fung K, Krzyzanowska MK, Amir E, et al. The impact of diabetes on breast cancer treatments and outcomes: A population-based study. Diabetes Care 2018;41:755-61.

30. Goebel J, Valinski S, Hershey DS. Improving coordination of care among healthcare professionals and patients with diabetes and cancer. Clin J Oncol Nurs 2016;20:645-51.

31. Kus T, Aktas G, Kalender ME, Sevinc A, Kul S, Suner A, et al. Taxane-induced peripheral sensory neuropathy in cancer patients is associated with duration of diabetes mellitus: A single-center retrospective study. Support Care Cancer 2016;24:1175-9.

32. Park JH, Kim HY, Lee H, Yun EK. A retrospective analysis to identify the factors affecting infection in patients undergoing chemotherapy. Eur J Oncol Nurs 2015;19:597-603.

33. Hershey DS, Pierce SJ. Examining patterns of multivariate, longitudinal symptom experiences among older adults with type 2 diabetes and cancer via cluster analysis. Eur J Oncol Nurs 2015;19:7-16.

34. Higo N, Kaneko T, Hasegawa M, Mitsuki S, Iwase H, Kadono M, et al. Self-perception of glycemic control in type-2 diabetes patients during and after cancer treatment. J Japan Diabetes Soc 2015;58:183-91.

35. Brady V, Thosani S, Zhou S, Bassett R, Busaidy NL, Lavis V. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy. Diabetes Technol Ther 2014;16:874-9.

36. Takenaka Y, Cho H, Yamamoto M, Nakahara S, Yamamoto Y, Inohara H. Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. Support Care Cancer 2013;21:2861-8.

37. Dote S, Sawai M, Hattori T, Nozaki A, Kobayashi Y, Doi S, et al. Blood glucose management in steroid therapy for hematologic malignancies complicated by diabetes: Usefulness of medication support by pharmacists in collaborative drug therapy management. J Pharm Health Care Sci 2013;39:395-405.

38. Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant folfox IV. Support Care Cancer 2013;21:1313-9.

39. Tamimoto H, Yokoyama T, Honda H, Teramoto M, Teramoto H. Chemotherapy for gynecologic malignant tumors accompanied with diabetes mellitus. Jpn J Gynecol Oncol 2013;31:164-8.

40. Uwah AN, Ackler J, Leighton JC Jr., Pomerantz S, Tester W.
The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 2012;11:275-9.

41. Tsuda Y, Matsuda K, Tujima M, Min K, Harada Y, Kuniyoshi S, et al. Risk factor for peripheral neuropathy induced by paclitaxel in patients with breast cancer. Jpn J Pharm Health Care Sci 2012;38:359-64.

42. Wuketich S, Hienz SA, Marosi C. Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors. Support Care Cancer 2012;20:175-83.

43. Fujii T, Suzuki H, Sawayanagi N, Nakamura H, Tsukamoto H, Shibata K, et al. The influence of dexamethasone on control of blood glucose levels in cancer patients with concurrent diabetes. J Japan Hosp Pharm Assoc 2012;48:627-31.

44. Saito M, Dale Y, Egashira N, Tatsushima Y, Murakami Y, Mishima K, et al. The influence of dexamethasone on blood glucose level in cancer patients with concurrent diabetes. J Japan Hosp Pharm Assoc 2011;47:1261-4.

45. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 2009;27:2170-6.

46. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25:3808-15.

47. Japanese Society of Clinical Oncology: Clinical Practice Guideline Ver 2.2: Antiemesis; 2018. Available from: http://jsco-cpg.jp/guideline/29.html#cq05. [Last accessed on 2020 Nov 23].

48. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014;155:2461-70.

49. Zeng L, Biernacka KM, Holly JM, Jarrett C, Morrison AA, Morgan A, et al. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: The role of fatty acid synthase. Endocr Relat Cancer 2010;17:539-51.

50. Takeda A. Symptoms of diabetes. In: Nanjo K, editor. Update Medical Course for Nursing. 2nd ed., Vol. 8. Tokyo: Diabetes and Complications Nakayama Shoten; 2011. p. 318-25.

51. Toyota T. Symptoms of diabetes. In: Nanjo K, editor. Update Medical Course for Nursing. 2nd ed., Vol. 8. Tokyo: Diabetes and Complications Nakayama Shoten; 2011. p. 112-21.

52. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, et al. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2012;12:355-62.

53. Jibiki A, Yokoyama Y, Kawazoe H, Suzuki S, Nakamura T. Steroids as cancer medication. Jpn J Drug Saf 2019;5:1-13.

54. Urabe A, Shimada K, Kawai S. Adrenal Corticosteroid. Today's Remedy 2014 Explanation and Handbook. Tokyo: Nankodo; 2014. p. 242-5.

55. The Japan Diabetes Society. Diabetes Treatment Guide 2020-2021. Tokyo: Bunkodo; 2020. p. 86-8.

56. Jeong Y, Han HS, Lee HD, Yang J, Jeong J, Choi MK, et al. A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res Treat 2016;48:1429-37.

57. Nakano H, Takeda M, Matsuoka K. Symptom management strategies for chemotherapy-induced peripheral neuropathy in cancer patients. University of Hyogo College of Nursing Art and Science, Research Institute of Nursing Care for People and Community Bulletin 2020;27:25-38.

58. Oishi R, Egashira N. Peripheral neuropathy induced by anticancer drugs. Fukuoka Igaku Zasshi 2013;104:71-80.